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Abstract
Background: Chronic hepatitis B virus (HBV) infection and chronic kidney disease (CKD) have high prevalences in
Taiwan and worldwide. However, the association of untreated chronic hepatitis B virus (HBV) infection with chronic
kidney disease (CKD) remains unclear.
Methods: This cohort study used claims data in the Taiwan National Health Insurance Research Database in
1996–2010, in which all diseases were classified by ICD-9-CM codes. We identified 17796 adults who had chronic
HBV infection and did not take nucleos(t)ide analogues from 1998 to 2010 and also randomly selected 71184
matched controls without HBV in the same dataset. Cumulative incidences and adjusted hazard ratio (aHR) of
incident CKD were evaluated through the end of 2010 after adjusting for competing mortality.
Results: The risk of CKD was significantly higher in the HBV cohort (13-year cumulative incidence, 6.2 %; 95 %
confidence interval [CI], 5.4–7.1 %) than in the non-HBV cohort (2.7 %; 95 % CI, 2.5–3.0 %) (p < 0.001), and the aHR
was 2.58 (95 % CI, 1.95-3.42; p < 0.001). Multivariable stratified analysis further verified significant associations of CKD
with HBV in men of any age (aHR, 2.98; 95 % CI, 2.32–3.83, p < 0.001 for men aged <50 years; aHR, 1.58; 95 % CI,
1.31–1.91, p < 0.001 for men aged ≧50 years) and women under the age of 50 (aHR, 2.99; 95 % CI, 2.04–4.42,
p < 0.001), but no significant association in women aged 50 or over.
Conclusion: Untreated chronic HBV infection is associated with increased risk of CKD. Hence, high-risk HBV-infected
subjects should have targeted monitoring for the development of CKD.
Keywords: HBV infection, Chronic kidney disease, Cohort study, Taiwan National Health Insurance Research
Database, Competing mortality
Background
Chronic kidney disease (CKD) is a global public health
burden because of its increasing incidence and preva-
lence and progressive nature to end-stage renal disease
(ESRD) [1]. Therefore, it is critical to identify risk factors
for CKD to allow for effective surveillance. Beyond the
traditional cardiovascular risk factors, infectious disease
is an under-recognized risk factor for CKD [2].
Hepatitis B affects approximately 350 million people
worldwide [3], and is associated with high mortality and
morbidity [4]. Apart from major liver complications,
clinical evidence suggests that chronic HBV infection
has a negative impact on renal function. HBV infection
can lead to glomerulonephritis, even in the absence of
cirrhosis [5]. A small controlled prospective study indi-
cated that individual estimated glomerular filtration rate
declined by approximately −2 ml/min/y in 60 untreated
HBV-infected patients without pre-existing renal disease,
diabetes, or hypertension during the median follow-up
of 24 months [6]. A 2-year cross-sectional HARPE study
indicated that renal abnormalities were highly prevalent
in treatment-naïve patients with chronic HBV infection
[7]. A 2-year GLOBE study indicated that Telbivudine
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improved renal function in patients with chronic HBV
infection [8]. Together, these findings provide a theoret-
ical basis for further research of the negative impact of
HBV infection on renal function.
Chronic HBV infection is associated with increased in-
sulin resistance [9] and intensification of oxidative stress
[10], and these may contribute to renal injury [11].
Therefore, it seems biologically plausible that HBV-
infected subjects have increased risk for CKD. Our prior
nationwide cohort study has demonstrated that un-
treated chronic HBV infection is associated with in-
creased risk of ESRD [12]. However, four cross-sectional
studies [9, 13–15] on the role of HBV in the develop-
ment of CKD have had disparate results.
To date, there have been no cohort studies of the asso-
ciation of chronic HBV infection with risk of incident
CKD, and it is unclear which HBV-infected patients are
more likely to develop CKD. This is a crucial issue, be-
cause the management of patients with coexisting HBV
infection and CKD is a challenge [16] and the global
burden of HBV infection and CKD is rising [17]. Taiwan
has high prevalence of CKD and HBV infection, and
thus provides an ideal setting for study of the relation-
ship of both diseases. In the present study, we conducted
a 13-year nationwide cohort study to examine whether
untreated chronic HBV infection is associated with in-
creased risk of incident CKD using reimbursement




This nationwide cohort study used outpatient and in-
patient claims from the NHIRD from 1996 to 2010, which
is released by the National Health Research Institutes
(NHRI) for Taiwan’s National Health Insurance (NHI)
Program. The NHI is a government-run, compulsory-
enrolment, single-payer system that had a coverage rate of
more than 99 % by the end of 2010, and codes diagnoses
according to ICD-9-CM (Additional file 1: Table S1). The
NHIRD lacks information on laboratory and lifestyle data
and severity of the disease condition. Our previous re-
search provided details of the NHIRD [2, 12, 18–21]. In
brief, the NHIRD has detailed healthcare data of 25.68
million enrollees (99.9 % of the population) based on a
random sample of all enrollees of the NHI program. There
were no significant differences in age, sex, or healthcare
costs between the sample group and all enrollees. The
NHRI approved this study. Informed consent was not re-
quired because this is a secondary data analysis.
Study cohorts
Here, we used methods substantially similar to those we
used in our earlier paper regarding the association of
HBV with ESRD [12], in which, briefly, we used the
claims data from the NHIRD and identified 88790 study
subjects from 1999 to 2010. In the present study, we
identified all adults with chronic HBV infection between
1 January 1998 and 31 December 2010 from the NHIRD.
The index date was defined on the date of chronic HBV
infection claim during the entry period. We excluded
subjects who had HCV infection from 1996 to 2010 and
CKD/ESRD from 1996 to the index date, or took
nucleos(t)ide analogues (lamivudine, adefovir, entecavir,
telbivudine) [12] before CKD event occurred. The NHI
program in Taiwan was initiated in 1995, so the dataset
only allows tracking of medical services from 1996 to
2010. In Taiwan, the NHI program has reimbursed
nucleos(t)ide analogues for patients with chronic HBV
infection since October 1, 2003 [22]. Thus, we could
identify HBV patients using nucleos(t)ide analogues in
the NHIRD. There were 17796 untreated subjects with
chronic HBV infection.
The non-HBV (control) cohort was extracted from the
remaining subjects in the database. We first excluded
subjects who had claim-based diagnoses of HCV or
HBV infection from 1996 to 2010, or CKD/ESRD from
1996 to the index date. To consider the potential con-
founding by age, sex, and calendar year, we performed
the individual matching technique in selecting controls.
For each HBV case, we selected, by using simple random
sampling method, 4 controls with the same gender and
age category (18–39, 40–49, 50–59, 60–69, or ≧70 years)
as the HBV case. Additionally, the eligible controls must
be actively insured for at least 1 day in the year when
the HBV case was identified. We also managed to ex-
clude the situation in which one control served multiple
cases. By doing so, once a beneficiary was selected in a
given year during the HBV patient recruitment period
(i.e., 1998–2010), he/she was then eliminated from the pool
of potential controls, which provide reassurance that no
control subjects were repeatedly selected. Thus, for con-
trols, the index date was within the same year of the index
date of their matched cases. We used age stratification be-
cause previous research indicated an age-dependent associ-
ation of HBV infection [4] and of CKD [19]. The control
group ultimately included 71184 subjects.
Definition of CKD
The claims-based diagnosis of CKD was defined by the
presence of 1 inpatient or 2 outpatient ICD-9-CM code
585 [23] in the claims and without catastrophic illness
registration cards for ESRD (indicating the need for
renal replacement therapy). The Taiwan Society of
Nephrology launched a nationwide CKD Preventive Pro-
ject covering CKD stages 1–5 in 2004. The simplified
Modification of Diet in Renal Disease equation along
with proteinuria has been used to estimate the national
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prevalence of 5-stage CKD in Taiwan [1]. The ICD-9-
CM code 585 is consistent with the National Kidney
Foundation’s Kidney Disease Outcome Quality Initiative
definition of CKD stages 1–5 [19], allowing for compari-
sons of the incidence and prevalence of CKD in Taiwan
and the United States [24]. However, the CKD stage
(severity) cannot be assessed in the NHIRD.
Main outcome measurement
Both cohorts were followed from the index date to the
first diagnosis of CKD, death, or the end of 2010. Death
is a competing event for any event of progression be-
cause patients who die during follow-up can no longer
progress after death [25]. Therefore, death before reach-
ing CKD, which could lead to informative censoring,
was considered as a competing risk event in estimating
the incidence of CKD. Death was defined by withdrawal
from the NHI program [12].
Potential confounders
We considered several confounders associated with CKD
[19], including major comorbidities between 1 January
1996 and the index date (diabetes, hypertension, coronary
heart disease, hyperlipidemia, and cirrhosis), number of
medical visits, urbanization level (urban, suburban, and
rural) and enrollee category (EC), from EC1 (highest sta-
tus) to EC4 (lowest status), as proxy measures of socioeco-
nomic status. Previous Taiwanese studies reported an
association of CKD with geographic region of residence
[19, 26]. Thus, geographic region of residence (northern,
central, southern, or eastern Taiwan) was included to
minimize potential confounding due to differences in ac-
cessibility and availability of medical care [18]. Herbs con-
taining aristolochic acid, including (Guan) Mu Tong and
(Guang) Fangchi, were associated with increased risk of
CKD and could be identified from the NHIRD only before
November 2003 [27]. Nevertheless, use of these herbs
greater than 30 days from 1996 to endpoint outcome was
also recorded. We also considered Deyo-Charlson Comor-
bidity Index (CCI) score and propensity score to control
confounding and reduce bias in the background covariates
between both cohorts in studies using healthcare adminis-
trative databases [28–30]. HBV status as the dependent
variable and background covariates (including age, sex,
major comorbidities, geographic region, urbanization
level, EC, number of medial visits, and CCI score) as the
independent variables were included in the calculation of
propensity score using logistic regression. The propensity
score model had a c-index of 0.66, indicating fair discrim-
ination between the two cohorts [12].
Statistical analyses
We calculated and compared the cumulative incidence
of CKD in data with competing risk by the modified
Kaplan-Meier method and Gray’s method [31], and
tested differences in the full time-to-event distributions
between the study cohorts using modified log-rank test.
We checked the interaction terms of HBV with sex,
HBV with age, and HBV with age and sex, all of which
were statistically significant. After confirming the as-
sumption of proportional hazards, we applied the modi-
fied Cox proportional hazard model in the presence of
competing mortality to examine the association of HBV
with CKD [32], with adjustment for all covariates (age
per year, sex, major comorbidities, use of herbs contain-
ing aristolochic acid, geographic region, urbanization
level, EC, number of medical visits, CCI score, and pro-
pensity score) and three significant above-mentioned
interaction terms. Next, we determined the influence of
HBV on CKD according to sex and age in the presence
of competing mortality. For this analysis, we classified
patients as younger than 50 years or as 50 years and
older, because previous research indicated that steatosis
is a characteristic feature of chronic HBV infection [33]
and that the biggest gender difference in steatosis preva-
lence was observed in individuals younger than 50 years
[34]. As we simultaneously included comorbidities, so-
cial characteristics, CCI and propensity score in the
multivariate regression model, a potential numerical
problem concerned multicollinearity between covariates,
which might render estimated regression coefficients in-
valid. We examined the potential multicollinearity
among covariates and found that multicollinearity
should not be a concern in our data as the multivariate
Cox regression model had no large estimated slope coef-
ficients and estimated standard error of the mean [35].
Besides, the tolerance level was greater than 0.1 for all
covariates. We analyzed all data with SAS (version 9.2;
SAS Institute, Inc., Cary, N.C.) and considered a two-
sided p-value less than 0.05 as statistically significant.
Results
Baseline characteristics of the study cohorts
The male-to-female ratio in the HBV cohort was 1.4.
Compared with the non-HBV (control) cohort, the HBV
cohort was more likely to have comorbidities including
diabetes, hypertension, hyperlipidemia, and cirrhosis, as
well as frequent use of herbs containing aristolochic acid,
higher socioeconomic status (EC 1 and 2), more medical
visits, higher propensity score and CCI score, and to reside
in urban areas and northern, central, and eastern regions;
all with considerable significance (Table 1).
Cumulative incidences of CKD between the HBV and
control cohorts in the presence of competing mortality
The 1-, 3-, 5-, 7-, 9-, 11-, and 13-year cumulative inci-
dences of CKD were 0.26 % vs. 0.10 %, 0.77 % vs. 0.33 %,
1.35 % vs. 0.65 %, 2.00 % vs. 1.00 %, 2.90 % vs. 1.48 %,
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4.30 % vs. 2.12 %, and 6.20 % vs. 2.74 %, respectively, in
the HBV cohort compared with the control cohort (all
p < 0.001, Table 2). Therefore, the risk of CKD was sig-
nificantly higher in the HBV cohort (13-year cumulative
incidence, 6.2 %; 95 % CI, 5.4–7.1 %) than the control
cohort (2.7 %; 95 % CI, 2.5–3.0 %) (p < 0.001, Fig. 1).
Chronic HBV infection as an independent risk factor for CKD
The mean duration of follow-up was 6.55 and 6.56
years for the HBV and control cohorts, respectively
(Additional file 2: Table S2). Among the 88980 subjects,
1247 subjects (1.4 %) developed CKD during the study
period, with 425 (2.4 %) and 822 (1.2 %) from the HBV and
control cohorts, respectively. The modified multivariable-
adjusted Cox proportional hazard model in the presence
of competing mortality revealed that CKD was independ-
ently associated with HBV (adjusted hazard ratio [aHR],
2.58; 95 % confidence interval [CI], 1.95–3.42; p < 0.001),
men (1.38; 1.11–1.73; p = 0.004); age (1.06; 1.05–1.07;
p < 0.001), diabetes (2.41; 1.94–2.99; p < 0.001), hyperten-
sion (1.92; 1.64–2.24; p < 0.001), residence in central (1.31;
1.12–1.53; p < 0.001), eastern (1.49; 1.06–2.09; p = 0.023),
southern (1.21; 1.04–1.42; p = 0.016) Taiwan, and the
number of medical visits (1.01; 1.009–1.014; p < 0.001)
(Table 3).
We further performed a sensitivity analysis to test the
robustness of these results. We excluded diabetic or
cirrhotic subjects from both cohorts at baseline, also indi-
cating a positive association of HBV with CKD (2.61,
1.97–3.46; 2.58, 2.04–3.99; respectively) (data not shown).
Association of CKD with HBV by sex and age
After adjusting for competing mortality, multivariable
stratified analysis further verified significant associations
of CKD risk with HBV in men (adjusted HR, 3.05; 95 %
CI, 2.50–3.71; p < 0.001), women (2.56; 1.93–3.41; p <
0.001), subjects younger than 50 years (2.86; 1.98–4.13;
p < 0.001), men younger (2.98; 2.32–3.83; p < 0.001) and
older than 50 years (1.58; 1.31–1.91; p < 0.001), and
women younger than 50 years (2.99; 2.04–4.42; p <
0.001), and no significant association in subjects older
than 50 years (1.19; 0.90–1.56; p = 0.22) and women
older than 50 years (1.18; 0.90–1.55; p = 0.24) (Table 4).
Table 1 Sociodemographic characteristics and comorbidities
between cohorts with and without hepatatis B virus (HBV)














Women 7368 (41.4) 29472 (41.4)
Age (year) 1.00
18–39 8514 (47.8) 34056 (47.8)
40–49 4914 (27.6) 19656 (27.6)
50–59 2857 (16.1) 11428 (16.1)
60–69 1146 (6.4) 4584 (6.4)
≧ 70 365 (2.1) 1460 (2.1)
Major comorbidities
Diabetes 1660 (9.3) 5181 (7.3) <0.001
Hypertension 2511 (14.1) 9020 (12.7) <0.001
Coronary heart disease 1039 (5.8) 4392 (6.2) 0.10
Hyperlipidemia 2484 (14.0) 66.71 (9.4) <0.001
Cirrhosis 638 (3.6) 466 (0.7) <0.001
Use of herbs containing
aristolochic acid
365 (2.1) 931 (1.3) <0.001
Geographic region
Northern 8967 (50.4) 35017 (49.2)
Central 4191 (23.6) 16280 (22.9)
Eastern 434 (2.4) 1588 (2.2)
Southern 4204 (23.6) 18299 (25.7)
Urbanization level 0.001
Urban 5939 (33.4) 22745 (32.0)
Suburban 8216 (46.2) 33438 (47.0)
Rural 3640 (20.4) 15002 (21.0)
Enrollee category
1 9420 (52.9) 35633 (50.0)
2 546 (3.1) 1830 (2.6)
3 5297 (29.8) 22157 (31.1)
4 2533 (14.2) 11564 (16.3)
No. of medical visits (mean ± SD) 17.7 ± 15.1 15.8 ± 15.3 <0.001
Propensity score (mean ± SD) 0.23 ± 0.09 0.19 ± 0.07 <0.001
Charlson Comorbiditv Index
score (mean ± SD)
1.1 ± 1.2 0.6 ± 1.2 <0.001
Categorical variables given as number (percentage); continuous variable, as
mean ± standard deviation
Table 2 Cumulative incidences of chronic kidney disease (CKD)
between the HBV and non-HBV cohorts in the presence of
competing mortality
HBV cohort, (95 % CI) Non-HBV cohort, (95 % CI) P*
CKD event
At 1 year 0.26 % (0.19–0.35 %) 0.10 % (0.08–0.12 %) <0.001
At 3 years 0.77 % (0.64–0.92 %) 0.33 % (0.29–0.38 %) <0.001
At 5 years 1.35 % (1.17–1.55 %) 0.65 % (0.59–0.72 %) <0.001
At 7 years 2.00 % (1.76–2.26 %) 1.00 % (0.91–1.09 %) <0.001
At 9 year 2.90 % (2.58–3.24 %) 1.48 % (1.37–1.60 %) <0.001
At 11 year 4.30 % (3.85–4.79 %) 2.12 % (1.96–2.29 %) <0.001
At 13 year 6.20 % (5.39–7.08 %) 2.74 % (2.49–3.01 %) <0.001
*Two sample proportion test. Abbreviations: CI confidence interval
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Discussion
To our knowledge, this is the first large nationwide co-
hort study to demonstrate an increased risk for CKD in
untreated subjects with chronic HBV infection and sim-
ultaneously to determine the overall risk and age- and
sex-specific risks of CKD. In this study, CKD was 2.58-
fold more likely in HBV-infected subjects, relative to
controls, after controlling for potential confounders and
competing mortality. We also found that the risk of
CKD in HBV-infected subjects was somewhat similar
(range from 2 to 3) in men of any age and women under
the age of 50. Noteworthily, HBV was not associated
with CKD risk in women aged 50 or over. This informa-
tion has important clinical implications for the design of
surveillance programs that assess chronic HBV infection
and CKD.
The association between chronic HBV infection and
the development of CKD remains controversial. Two
cross-sectional studies [7, 15] demonstrated a positive
association of HBV with CKD. A 2-year multicentric
cross-sectional French study reported that CKD was
highly prevalent in 268 treatment-native patients with
chronic HBV infection [7]. A cross-sectional Taiwanese
study [15] reported that HBV was associated with CKD
in 416 HBV-infected adults; however, another cross-
sectional Taiwanese study by the same research group
reported that HBV was not associated with CKD or pro-
teinuria in 5424 HBV-infected adults [14]. Similarly, a
cross-sectional study of 328 HBV-infected adults in
Beijing [13] reported that HBV was not associated with
CKD or albuminuria. On the other hand, a cross-
sectional Japanese study of 130 HBV-infected adults [9]
showed that HBV was not associated with albuminuria,
but was inversely associated with CKD. The discrepan-
cies among these studies may be attributed to the cross-
sectional nature of their design, use of small sample
sizes, and differences among the specific populations.
Moreover, cross-sectional analyses cannot establish
whether HBV infection preceded development of CKD.
The present study was cohort design and used a large
dataset, which afforded considerable statistical power
and allowed tracking of incident CKD events over
13 years. We demonstrated an increased risk of CKD in
untreated patients with chronic HBV infection that was
independent of the presence of diabetes or cirrhosis.
Our HBV cohort tended to be younger and male, and
to have a higher socioeconomic status, consistent with
our prior research [12]. On stratified analysis, we found
significant associations of HBV with CKD risk in men of
any age (especially under the age of 50) and women
Fig. 1 Cumulative incidence of CKD in the HBV and non-HBV cohorts. Data were compiled after adjustment for competing mortality
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under the age of 50, similar to our prior research [12].
Previous research reported that men have increased risk
for development of CKD [19], and that men have a
lower clearance rate than females, so are therefore more
susceptible to development of chronic HBV infection
[36]. Steatosis, a characteristic feature of chronic HBV
infection, can increase lipid peroxidation and plasma in-
flammatory biomarkers [33], and these may contribute
to endothelial dysfunction and renal injury [11]. The big-
gest sex difference in steatosis occurs in subjects youn-
ger than 50 years [33]. Taken together, these results may
explain our observations regarding the effect of age and
gender on the risk for development of CKD following
untreated chronic HBV infection.
The pathogenesis of HBV-mediated renal injury prob-
ably depends on interactions of the virus with the host
and various environmental factors [3]. Our results indi-
cated that CKD ensued following untreated chronic
HBV infection during the mean follow-up of 5.7 years,
the interval of which was similar to 60 months in a case
series [5]. HBV-related renal injury is believed to be due
to the deposition of immune complexes of HBV antigens
and host antibodies [3]. Other research also explored the
possible effect of HBV on the development of nephropa-
thy. HBV antigens (HBsAg, HBcAg, and HBeAg) and
HBV DNA have been detected in glomeruli [37] and
tubular epithelia [38], respectively. HBV DNA negative
or positive sera of patients with chronic HBV infection
promoted apoptotic damage in renal tubular cells via
up-regulation of Fas gene expression, and these patients
also had a higher circulating level of transforming
growth factor-β, which is implicated in the potentiation
Table 3 Crude and adjusted hazard ratios (HR) for chronic kidney disease (CKD), with adjustment for competing morality
Variable Crude Adjusted*
HR (95 % CI) P HR (95 % CI) P
HBV (Yes/No) 2.08 1.85–2.34 <0.001 2.58 1.95–3.42 <0.001
Sex (Men/Women) 1.32 1.18–1.49 <0.001 1.38 1.11–1.73 0.004
Age (per year) 1.07 1.06–1.07 <0.001 1.06 1.05–1.07 <0.001
Major comorbidities (Yes/No)
Diabetes 5.30 4.69–5.98 <0.001 2.41 1.94–2.99 <0.001
Hypertension 5.00 4.47–5.60 <0.001 1.92 1.64–2.24 <0.001
Coronary heart disease 2.88 2.47–3.37 <0.001 0.90 0.66–1.23 0.51
Hyperlipidemia 2.77 2.41–3.18 <0.001 1.19 0.95–1.49 0.13
Cirrhosis 2.29 1.67–3.15 <0.001 1.00 0.33–3.02 0.10
Use of herbs containing aristolochic acid (Yes/No) 1.13 0.75–1.70 0.57 0.88 0.59–1.33 0.55
Geographic region
Northern 1.00 Reference 1.00 Reference
Central 1.22 1.08–1.39 0.002 1.31 1.12–1.53 <0.001
Eastern 1.40 1.03–1.92 0.034 1.49 1.06–2.09 0.023
Southern 1.19 1.05–1.34 0.006 1.21 1.04–1.42 0.016
Urbanization level
Urban 1.00 Reference 1.00 Reference
Suburban 0.94 0.84–1.05 0.27 0.98 0.85–1.14 0.82
Rural 1.39 1.23–1.58 <0.001 0.92 0.77–1.11 0.38
Enrollee category
1 1.00 Reference 1.00 Reference
2 0.55 0.34–0.87 0.011 0.86 0.53–1.38 0.53
3 1.52 1.36–1.70 <0.001 1.14 0.97–1.35 0.11
4 1.45 1.27–1.66 <0.001 1.12 0.91–1.38 0.28
No. of medical visits 1.02 1.01–1.02 <0.001 1.01 1.009–1.014 <0.001
Charlson Comorbidity Index score 1.31 1.29–1.34 <0.001 0.97 0.81–1.14 0.68
Propensity score 1.42 1.36–1.47 <0.001 1.10 0.77–1.57 0.60
Abbreviations: HBV hepatitis B virus, CI confidence interval
*Adjusted for all covariates (age per year, sex, major comorbidities, use of herbs containing aristolochic acid, geographic region, urbanization level, enrollee
category, number of medical visits, Charlson Comorbidity Index score, and propensity score), and interaction terms (HBV/age, HBV/sex, and HBV/age/sex)
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of apoptosis and renal fibrosis [39]. HBV is associated
with increased insulin resistance [9] and oxidative stress
[10], and these are implicated in the progression of ne-
phropathy [11]. However, only a small number of the
350 million HBV carriers develop glomerulonephritis
[4]. This indicates that chronic HBV infection by itself is
insufficient for development of nephropathy, and that
additional socio-environmental conditions, alterations in
cell-mediated immunity, genetic susceptibility, and other
factors are also important [3]. This may explain the lower
13-year cumulative incidence rate (6.2 %) of CKD follow-
ing untreated chronic HBV infection in this study. How-
ever, the HBV-positive population is increasing by 50
million per year, despite a marked increase in vaccination
rates [40]. Therefore, it is conceivable that the burden of
CKD following chronic HBV infection is increasing.
The major strength of our study is that it was designed
to reduce selection bias (due to use of a large nationwide
population-based and highly representative sample with
random sampling), environmental effects (due to the
availability of socioeconomic indicators for all subjects)
[18], and detection bias (due to consideration of
complete histories of the use of medical services) [19].
In addition, the study population was well defined and
follow-up was complete because our design relied on
computerized registries that provided complete nation-
wide coverage. Therefore, our finding of increased risk
of CKD in HBV-infected subjects is robust.
Some potential limitations should be noted. First, mis-
classification of diseases may occur when an administra-
tion database is used. However, the NHI Administration
established an audit and penalty system for quality
monitoring to ensure accuracy of claims and minimize
misclassification error [41]. Moreover, both CKD and viral
hepatitis are important health problems in Taiwan, so the
government has strict guidelines for diagnosis [42]. Sec-
ond, some of our control subjects may have had sub-
clinical HBV infection. However, if HBV is associated with
CKD, this misclassification would lead to lower HRs, thus
supporting the robustness of our findings. Third, although
nucleos(t)ide analogues for HBV patients have been cov-
ered under the NHI program since October 1, 2003, this
reimbursement requires patients to fulfill certain criteria,
such as two-fold increase or more in serum alanine ami-
notransferase level and HBV DNA titer greater than
2000 IU/mL [43]. Some HBV patients may use self-paid
nucleos(t)ide analogues before October 1, 2003 or when
they do not fulfill reimbursed criteria, and thus may be in-
appropriately classified into the untreated cohort. These
potential misclassifications may lead to an underestima-
tion of the association [22]. Fourth, the NHIRD lacks in-
formation on family history of kidney diseases, lifestyle,
body weight, and laboratory data (e.g., levels of serum
HBV DNA and HBV genotype), which may contribute to
CKD risk. Thus, this may lead to the difference of propen-
sity score between both cohorts. Nevertheless, we added
CCI score into the propensity analysis in order to reach
the comparability of both cohorts and included CCI
score and propensity score in multivariable and strati-
fied analyses to control confounding in healthcare
administrative databases [12, 28, 29]. Although unmeas-
ured confounders my still exist as with any observa-
tional study, we believe the methodology used in the
present study is solid and robust.
Table 4 Association of chronic kidney disease (CKD) with HBV, stratified by sex and age, with adjustment for competing mortality
HBV cohort Non-HBV cohort Hazard ratio (95 % CI)
n PY CKD events n PY CKD events Crude P Adjusted* P
Sex
Men 10428 68249 294 41712 274693 525 2.26 (1.96–2.61) <0.001 3.05 (2.50–3.71)† <0.001
Women 7368 48243 131 29472 192357 297 1.77 (1.44–2.18) <0.001 2.56 (1.93–3.41)† <0.001
Age (year)
< 50 13428 84358 203 53712 337813 191 4.30 (3.53–5.24) <0.001 2.86 (1.98–4.13) <0.001
≧50 4368 32133 222 17472 129237 631 1.40 (1.20–1.63) <0.001 1.19 (0.90–1.56) 0.22
Men
< 50 years 7888 49981 140 31552 200858 132 4.28 (3.38–5.43) <0.001 2.98 (2.32–3.83) <0.001
≧50 years 2540 18268 154 10160 73835 393 1.57 (1.30–1.89) <0.001 1.58 (1.31–1.91) <0.001
Women
< 50 years 5540 34378 63 22160 136955 59 4.34 (3.05–6.19) <0.001 2.99 (2.04–4.42) <0.001
≧50 years 1828 13865 68 7312 55402 238 1.13 (0.86–1.48) 0.37 1.18 (0.90–1.55) 0.24
Abbreviations: HBV hepatitis B virus, PY person-year, CI confidence interval
*Adjusted for all covariates (age, sex, major comorbidities, use of herbs containing aristolochic acid, geographic region, urbanization level, enrollee category,
number of medical visits, Charlson Comorbidity Index score, and propensity score) and interaction terms (HBV/age, HBV/sex, HBV/age/sex), minus the covariate
and interaction terms on which stratified
†Age was treated as a continuous variable in multivariate analysis
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Conclusions
This large national cohort study indicates that untreated
chronic HBV infection is associated with increased risk
of CKD, especially males and younger age. High-risk
HBV-infected subjects should have targeted monitoring
for the development of CKD.
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